List of Excipients in Branded Drug CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE	clonidine hydrochloride	66993-776	HYPROMELLOSE 2208
Prasco Laboratories	CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE	clonidine hydrochloride	66993-776	LACTOSE MONOHYDRATE
Prasco Laboratories	CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE	clonidine hydrochloride	66993-776	MAGNESIUM STEARATE
Prasco Laboratories	CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE	clonidine hydrochloride	66993-776	SILICON DIOXIDE
Prasco Laboratories	CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE	clonidine hydrochloride	66993-776	SODIUM LAURYL SULFATE

Clonidine Hydrochloride Extended-Release Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Clonidine hydrochloride extended-release is a low-cost, mature oral product with limited composition-of-matter protection and modest formulation complexity. The commercial opportunity is strongest in generic tablets, pediatric-friendly dosage formats, differentiated release profiles, and reliable excipient supply rather than in premium pricing for a conventional matrix tablet. Kapvay, the reference product, was approved by the FDA for attention-deficit/hyperactivity disorder, either alone or as adjunctive therapy to stimulant medication.[1]

What is clonidine hydrochloride extended-release used for?

Clonidine hydrochloride extended-release tablets are approved for ADHD in patients age six years and older. The product may be used as monotherapy or alongside stimulant therapy.[1]

The reference product is administered twice daily, with either an equal morning and bedtime dose or a larger bedtime dose. The labeled strengths are 0.1 mg and 0.2 mg.[1]

Attribute	Reference product profile
Active ingredient	Clonidine hydrochloride
Dosage form	Extended-release oral tablet
Reference brand	Kapvay
FDA application	NDA 022331
Approved use	ADHD, monotherapy or adjunctive therapy
Labeled strengths	0.1 mg and 0.2 mg
Administration	Twice daily
Age group	Patients age six and older
Release restriction	Tablets should not be crushed, chewed, or broken
Pharmacologic class	Centrally acting alpha-2 adrenergic agonist

The product’s pharmacology creates a formulation requirement beyond simple immediate-release delivery. Excessive early release can increase sedation, hypotension, bradycardia, and dizziness, while excessive retardation can reduce symptom control.[1]

What excipients are used in clonidine hydrochloride extended-release tablets?

The reference formulation uses a conventional hydrophilic matrix architecture. The inactive ingredients identified in the FDA labeling include lactose monohydrate, hypromellose, corn starch, colloidal silicon dioxide, magnesium stearate, and tablet-coloring components depending on strength and manufacturer.[1,2]

Excipient function	Typical material in the reference formulation	Strategic role
Matrix former	Hypromellose	Controls water penetration, gel formation, and drug diffusion
Diluent	Lactose monohydrate	Provides tablet mass and improves compression properties
Disintegrant or processing aid	Corn starch	Supports tablet breakup after the intended release phase
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Lubricant	Magnesium stearate	Reduces ejection force and tooling adhesion
Colorant	Product-specific pigment or lake	Supports strength identification and appearance

Clonidine hydrochloride is a potent drug administered at a low dose. The active ingredient represents a small percentage of total tablet weight in many formulations. Content uniformity, blend segregation, and low-dose assay control are therefore important development issues.

How does hypromellose control clonidine release?

Hypromellose hydrates at the tablet surface and forms a viscous gel layer. Drug release then occurs through a combination of diffusion, matrix erosion, and fluid penetration. Polymer viscosity grade, substitution pattern, particle size, loading, compression force, and tablet geometry all affect the dissolution profile.

A commercial developer can use these variables to create differentiated profiles without changing the active ingredient:

• Lower-viscosity hypromellose can accelerate initial release.
• Higher-viscosity hypromellose can strengthen the release barrier.
• Polymer blends can reduce sensitivity to manufacturing scale.
• Increased tablet hardness can reduce early release but may impair downstream disintegration.
• Granulation can improve content uniformity but may change polymer hydration and dissolution.

The key development target is not simply a slower dissolution curve. It is a reproducible profile that remains within the reference product’s clinically acceptable performance range.

What excipient strategy is most appropriate for generic clonidine extended-release?

A conventional hydrophilic matrix is the lowest-risk platform for an ANDA-oriented product. It aligns with the established dosage form, uses widely available excipients, and avoids the cost and regulatory burden of an untested delivery technology.

Recommended base formulation

A practical starting platform would use:

1. Hypromellose as the primary release-controlling polymer.
2. Lactose or a comparable water-soluble filler for tablet weight and compactability.
3. Corn starch or another established disintegrant at a controlled concentration.
4. Colloidal silicon dioxide for powder flow.
5. Magnesium stearate at the lowest level that provides acceptable lubrication.

The formulation should be developed around the 0.1 mg strength first. The 0.2 mg strength can then be assessed as a proportional or near-proportional composition, subject to content-uniformity and dissolution results.

Which excipient risks matter most?

The main technical risks are low-dose uniformity, polymer variability, lubricant sensitivity, and dissolution drift.

Risk	Commercial consequence	Mitigation
Poor clonidine distribution	Batch rejection or potency variability	Ordered mixing, geometric dilution, segregation studies
Excess magnesium stearate	Slower wetting and altered dissolution	Short lubrication time and controlled lubricant level
Hypromellose lot variability	Dissolution inconsistency	Tight incoming specifications and supplier qualification
Starch moisture variation	Compression and release changes	Moisture controls and validated storage
Excessive tablet hardness	Delayed release or incomplete matrix erosion	Design-space control for compression force
Overly rapid release	Potential failure against reference dissolution	Polymer optimization and discriminatory testing
Colorant interaction	Appearance or release variability	Strength-specific compatibility studies

The developer should establish a formulation design space covering polymer grade, polymer concentration, lubricant level, compression force, tablet hardness, and coating parameters. FDA’s modified-release guidance emphasizes dissolution method development, discriminatory testing, and control of critical manufacturing variables.[3]

What formulations are protected by clonidine hydrochloride patents?

The principal formulation value in clonidine extended-release historically has been associated with controlled-release tablet architecture rather than the clonidine molecule itself. Clonidine hydrochloride is an old active ingredient, and its basic composition-of-matter protection is not commercially relevant.

The most defensible patent strategy focuses on formulation and process claims covering:

• Hydrophilic matrix compositions.
• Specific hypromellose concentration ranges.
• Multilayer or reservoir tablets.
• Controlled erosion or diffusion profiles.
• Coating systems that regulate water ingress.
• Low-dose blending and content-uniformity processes.
• Multiparticulate systems, including coated pellets or mini-tablets.
• Abuse-resistant or tamper-resistant delivery systems.
• Sprinkle or dispersible dosage forms, where clinically and regulatorily supportable.

A conventional generic tablet should be assessed against the current FDA Orange Book and relevant patent records before launch. The Orange Book identifies patents and regulatory exclusivities listed for approved drug products, but it does not replace a full freedom-to-operate review.[4]

When does clonidine extended-release lose exclusivity?

Kapvay’s original market exclusivity period has expired, and clonidine hydrochloride extended-release is a generic-entry product rather than a new-molecule exclusivity opportunity. The commercial question is therefore whether any listed formulation or method-of-use patents remain enforceable in the relevant jurisdiction and whether an applicant faces Paragraph IV litigation.

The practical assessment is:

Protection category	Current commercial significance
Clonidine composition of matter	None for ordinary generic development
Original drug exclusivity	Expired
Conventional extended-release tablet claims	Potentially relevant only if unexpired claims remain
ADHD method-of-use claims	Usually limited by claim scope and labeling strategy
New delivery-system patents	Potential opportunity for differentiated products
Pediatric-use protection	Relevant only if a specific regulatory exclusivity remains
Orange Book-listed patents	Must be checked against the current FDA listing

What is the Orange Book status of clonidine hydrochloride extended-release?

Kapvay is the reference product associated with FDA NDA 022331. The Orange Book should be reviewed for current patent listings, expiration dates, and any listed exclusivity associated with the reference product.[4]

For a generic sponsor, the filing strategy depends on the status of each listed patent:

• Paragraph I certification if no patent is listed.
• Paragraph II certification if the patent has expired.
• Paragraph III certification if the applicant will wait for patent expiry.
• Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable, or not infringed.

A Paragraph IV filing can create litigation exposure, but the commercial value of that strategy depends on the remaining patent term, market size, number of competing ANDAs, and probability of an injunction or launch delay. Because clonidine ER is a low-revenue product, litigation economics are less favorable than for high-value branded products.

Which companies are challenging clonidine extended-release?

Generic clonidine extended-release products have entered the market after the reference product’s exclusivity period. FDA product listings and approved labeling should be used to identify current ANDA sponsors, manufacturers, and marketed strengths.[5]

The competitive structure is typically fragmented:

• The reference sponsor retains brand recognition and prescriber familiarity.
• Generic manufacturers compete on price, supply reliability, and payer access.
• Contract manufacturers can compete through low-cost matrix-tablet production.
• Specialty companies can differentiate through pediatric dosage formats.

The market does not require a large sales force if the product is positioned as an interchangeable generic. Supply continuity, wholesaler access, and formulary coverage are more important than broad promotional spending.

What commercial opportunities exist for clonidine extended-release?

1. Conventional generic tablets

This is the most accessible opportunity. A sponsor can use an established matrix formulation and compete through:

• Lower cost of goods.
• Reliable supply of both 0.1 mg and 0.2 mg strengths.
• Improved packaging and child-resistant closures.
• Consistent dissolution across manufacturing sites.
• Dual sourcing of critical excipients.

The main limitation is price erosion. Conventional generic tablets are unlikely to support premium pricing unless the sponsor solves a recognized supply, adherence, or pediatric-use problem.

2. Pediatric-friendly dosage forms

The labeled product must be swallowed whole, which creates a potential usability gap for children who cannot reliably swallow tablets.[1]

Potential dosage formats include:

• Mini-tablets.
• Multiparticulate capsules.
• Sprinkle systems.
• Orodispersible or orally disintegrating tablets.
• Low-volume liquid systems.
• Unit-dose sachets.

Each format creates new stability, dose-uniformity, taste, and abuse-mitigation requirements. A liquid formulation also creates a preservation and packaging burden that does not exist with a dry matrix tablet.

The strongest pediatric opportunity is likely a solid multiparticulate product that preserves extended release while improving swallowability. A sprinkle product must prevent crushing of the release-controlling units during administration.

3. Alternate dosing and adherence products

The reference product requires twice-daily administration. A once-daily product could offer commercial differentiation, but it would require a new pharmacokinetic and clinical development strategy. The value proposition would be improved adherence and reduced daytime sedation through more controlled exposure.

A 505(b)(2) pathway may be relevant for a materially different dosage form or release profile, subject to FDA requirements for bridging studies and clinical support.[6]

4. Combination products

Clonidine ER is already used adjunctively with stimulant medication. A fixed-dose combination with a stimulant could reduce pill burden, but it would introduce major development and commercial complications:

• Different controlled-substance requirements for stimulant components.
• Distinct pharmacokinetic profiles.
• Dose titration challenges.
• Prescriber concerns about fixed dosing.
• Increased abuse-diversion controls.
• More complex patent and labeling analysis.

A combination product is more defensible as a specialty development program than as a low-cost generic strategy.

5. Excipient-supplier opportunities

Excipient suppliers can pursue this market without developing the finished drug. The most relevant opportunities are:

• High-purity, low-variability hypromellose grades.
• Direct-compression lactose systems.
• Co-processed excipients for low-dose uniformity.
• Low-moisture excipients for stability-sensitive matrices.
• Lubricant systems that minimize dissolution impact.
• Functional polymers for multiparticulate delivery.
• Taste-masking excipients for pediatric formats.

A supplier that provides formulation support, regulatory documentation, and lot-to-lot performance data can capture more value than a commodity excipient vendor.

How does clonidine extended-release compare with other ADHD medicines?

Clonidine ER competes with stimulant and nonstimulant ADHD therapies, including guanfacine extended-release and atomoxetine. Its commercial differentiation is based on pharmacology, adjunctive use, sedation profile, and low acquisition cost rather than superior convenience.

Product class	Primary commercial strength	Key formulation issue
Clonidine ER	Adjunctive therapy, low cost, nonstimulant mechanism	Twice-daily dosing and sedation risk
Guanfacine ER	Once-daily nonstimulant therapy	Release control and dose-related hypotension
Stimulants	Strong efficacy and established use	Controlled-substance restrictions and abuse concerns
Atomoxetine	Nonstimulant, once- or twice-daily use	Longer onset and tolerability management

A once-daily clonidine delivery system would compete more directly with guanfacine ER. A pediatric-friendly clonidine product would compete on administration convenience rather than pharmacologic superiority.

What manufacturing and IP barriers affect market entry?

The active ingredient is inexpensive, but the product still has meaningful manufacturing controls.

Manufacturing barriers

The principal barriers are:

• Low-dose content uniformity.
• Reproducible hydrophilic-matrix formation.
• Scale-up from laboratory to commercial compression.
• Dissolution control across equipment and sites.
• Stability of the polymer system.
• Prevention of dose dumping after tablet damage.
• Reliable supply of pharmaceutical-grade hypromellose.

The product is generally compatible with conventional solid-dose manufacturing. It does not require sterile processing, cold-chain distribution, or biologic drug-substance handling.

Intellectual-property barriers

The most important IP risks relate to:

• Unexpired controlled-release formulation claims.
• Specific release profiles.
• Multiparticulate or pediatric delivery systems.
• Manufacturing processes that materially improve uniformity or stability.
• Method-of-use claims covering adjunctive ADHD treatment.
• New patents covering once-daily or abuse-deterrent formulations.

A generic sponsor should avoid relying on a formulation that is technically close to a still-enforceable claim if a design-around is available. The low commercial value of the product favors early design-around work over prolonged patent litigation.

What is the revenue exposure for clonidine extended-release?

Standalone revenue for clonidine ER is generally not separately disclosed by major pharmaceutical companies. The product is a small market compared with leading stimulant ADHD medicines and large nonstimulant franchises.

Revenue potential depends on four factors:

1. The number of marketed generic suppliers.
2. Reimbursement and formulary placement.
3. Product availability during shortages.
4. Differentiation through pediatric or once-daily delivery.

A conventional generic tablet can generate stable volume but is exposed to rapid price erosion. A differentiated pediatric or once-daily product can command better pricing, but the required clinical and regulatory investment is substantially higher.

How strong is the patent estate for clonidine extended-release?

The patent estate is weak for the active ingredient and potentially moderate for differentiated delivery systems. Conventional matrix-tablet development should be treated as a generic competition program, not as a long-duration exclusivity program.

Patent layer	Relative strength
Active ingredient	Very weak or commercially exhausted
Conventional tablet composition	Low to moderate, depending on remaining claims
Specific release profile	Moderate if clinically meaningful and difficult to design around
Pediatric multiparticulate system	Moderate to strong if supported by robust claims
Once-daily delivery	Potentially strong, but development-intensive
Manufacturing process	Moderate if the process materially improves quality
Combination product	Potentially strong, but commercially and regulatorily complex

Key Takeaways

• Clonidine hydrochloride extended-release is a mature, low-cost ADHD product with limited active-ingredient patent value.
• Hypromellose is the central release-controlling excipient in a conventional matrix strategy.
• Lactose, starch, colloidal silicon dioxide, and magnesium stearate support tablet manufacture but can affect dissolution and content uniformity.
• Generic tablets are the lowest-risk commercial opportunity but face price erosion.
• Pediatric-friendly multiparticulates, mini-tablets, sprinkle products, and once-daily systems offer stronger differentiation.
• The principal technical risks are low-dose uniformity, polymer variability, lubricant sensitivity, and dissolution drift.
• Orange Book review, Paragraph IV analysis, and freedom-to-operate work remain necessary for any launch based on a specific formulation.
• Excipient suppliers can compete through functional polymer quality, co-processed excipients, and formulation-support services.
• Biosimilar risk is not applicable because clonidine hydrochloride is a chemically synthesized small-molecule drug.
• A differentiated delivery system may support a 505(b)(2) strategy, but a conventional generic tablet is more likely to follow the ANDA pathway.

FAQs

Is clonidine hydrochloride extended-release a biologic drug?

No. Clonidine hydrochloride is a chemically synthesized small-molecule drug. Biosimilar approval pathways do not apply.

Can clonidine extended-release tablets be crushed for children?

The reference labeling instructs patients not to crush, chew, or break the extended-release tablet because that can alter drug release.[1]

Which excipient is most important for clonidine extended-release performance?

Hypromellose is generally the critical release-controlling excipient. Its viscosity grade, concentration, hydration behavior, and interaction with compression conditions can materially affect dissolution.

Could a liquid clonidine extended-release product be commercially differentiated?

Yes, but a liquid product would require control of sedimentation, dose uniformity, preservation, taste, packaging, and release behavior. A multiparticulate solid product may offer a simpler stability profile.

Is once-daily clonidine extended-release commercially attractive?

Potentially. Once-daily dosing could improve adherence and compete more directly with other long-acting nonstimulant ADHD products, but it would require substantial formulation, pharmacokinetic, and regulatory development.

References

1. U.S. Food and Drug Administration. (2010). Kapvay (clonidine hydrochloride) extended-release tablets prescribing information. NDA 022331. https://www.accessdata.fda.gov
2. DailyMed. (n.d.). Clonidine hydrochloride extended-release tablets: Inactive ingredients and labeling. National Library of Medicine. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (1997). Extended release solid oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. https://www.fda.gov
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob
5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf
6. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov